Natera, Inc. (NASDAQ:NTRA) Insider Sells $4,101,319.17 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 24,861 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17. Following the transaction, the insider now owns 140,684 shares of the company’s stock, valued at approximately $23,208,639.48. This represents a 15.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The stock was sold at an average price of $166.59, for a total value of $809,294.22.
• On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $141,379.16.

Natera Stock Down 2.5 %

Natera stock opened at $167.61 on Monday. Natera, Inc. has a 1-year low of $62.96 and a 1-year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market cap of $22.13 billion, a PE ratio of -95.23 and a beta of 1.65. The stock’s fifty day moving average is $166.20 and its two-hundred day moving average is $136.43.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the previous year, the firm earned ($0.95) earnings per share. The business’s revenue was up 63.9% compared to the same quarter last year. On average, sell-side analysts expect that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. Dimensional Fund Advisors LP increased its position in shares of Natera by 35.6% during the second quarter. Dimensional Fund Advisors LP now owns 264,801 shares of the medical research company’s stock worth $28,680,000 after purchasing an additional 69,523 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Natera during the second quarter worth about $767,000. Amalgamated Bank grew its holdings in shares of Natera by 6.0% during the second quarter. Amalgamated Bank now owns 7,590 shares of the medical research company’s stock worth $822,000 after buying an additional 428 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Natera by 58.3% during the second quarter. Bank of Montreal Can now owns 72,293 shares of the medical research company’s stock worth $8,068,000 after buying an additional 26,615 shares during the last quarter. Finally, Xponance Inc. grew its holdings in shares of Natera by 12.9% during the second quarter. Xponance Inc. now owns 15,704 shares of the medical research company’s stock worth $1,701,000 after buying an additional 1,794 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NTRA. Robert W. Baird raised their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Canaccord Genuity Group raised their price target on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Craig Hallum increased their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Morgan Stanley increased their price objective on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, Leerink Partners increased their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $162.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.